var data={"title":"Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Outbreak of fungal central nervous system and osteoarticular infections in the United States: Treatment</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 03, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H811222\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A multistate outbreak of fungal central nervous system (CNS) infection and septic arthritis was detected in the United States in late September 2012. Over 700 patients who received epidural injections of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> produced at a single compounding center (New England Compounding Center) developed meningitis with or without posterior circulation stroke <span class=\"nowrap\">and/or</span> spinal or paraspinal infections, and more than 30 patients who received intra-articular injections of the same drug developed osteoarticular infections [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/1,2\" class=\"abstract_t\">1,2</a>]. <em>Exserohilum</em> spp, a dematiaceous (brown-black) fungus, has been the most commonly identified fungus (<a href=\"image.htm?imageKey=ID%2F86772\" class=\"graphic graphic_picture graphicRef86772 \">picture 1</a>).</p><p>The United States Centers for Disease Control and Prevention (CDC) issued recommendations for the management of patients affected by the outbreak. These recommendations can be found on the <a href=\"http://www.cdc.gov/HAI/outbreaks/meningitis.html&amp;token=mjmpv7xMHRIW2nr+3NCnsfWqsKLkGZOgSMsYfcbF0fWgQkwwHePBf3hqI+BGDTu3JgtZ4s7MFjekFGRdSgJwNg==&amp;TOPIC_ID=87286\" target=\"_blank\" class=\"external\">CDC website</a>.</p><p>The treatment of patients with fungal CNS infection or septic arthritis associated with the outbreak will be reviewed here; the epidemiology, clinical manifestations, and diagnosis of such infections are presented separately. The treatment of infections due to dematiaceous fungi and <em>Aspergillus</em> spp that are not associated with the outbreak are also discussed separately. (See <a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis\" class=\"medical medical_review\">&quot;Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H672980052\"><span class=\"h1\">CASE DEFINITIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The United States Centers for Disease Control and Prevention (CDC) defined a<strong> probable case </strong>associated with the 2012 outbreak as a person who received an injection with <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> acetate that was definitely or likely produced by the New England Compounding Center (NECC) after May 21, 2012, and who developed <strong>any</strong> of the following syndromes [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/3\" class=\"abstract_t\">3</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Meningitis of unknown etiology following epidural or paraspinal injection. Clinically diagnosed meningitis is defined as the presence of one or more of the following symptoms: headache, fever, stiff neck, or photophobia <strong>and</strong> a cerebrospinal fluid (CSF) profile showing pleocytosis (&gt;5 white blood cells, adjusting for the presence of red blood cells by subtracting 1 white blood cell for every 500 red blood cells), regardless of glucose or protein concentration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Posterior circulation stroke without a cardioembolic source without documentation of a normal CSF profile following epidural or paraspinal injection.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteomyelitis, abscess, or other infection (eg, soft tissue infection) of unknown etiology in the spinal or paraspinal structures at or near the site of epidural or paraspinal injection. Paraspinal injections include, but are not limited to, spinal facet joint injection, sacroiliac joint injection, and spinal or paraspinal nerve <span class=\"nowrap\">root/ganglion</span> block.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Osteomyelitis or worsening inflammatory arthritis of a peripheral joint (eg, knee, shoulder, or ankle) of unknown etiology diagnosed following joint injection. Clinically diagnosed septic arthritis is defined as new or worsening pain with presence of new or worsening effusion. (See <a href=\"topic.htm?path=septic-arthritis-in-adults\" class=\"medical medical_review\">&quot;Septic arthritis in adults&quot;</a>.)</p><p/><p>A <strong>confirmed case</strong> is defined as a probable case with evidence of a fungal pathogen (by culture, histopathology, molecular, or antigen-based assay) associated with one of the clinical syndromes described above.</p><p class=\"headingAnchor\" id=\"H920083787\"><span class=\"h1\">ANTIFUNGAL SUSCEPTIBILITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antifungal susceptibility testing of the dematiaceous fungi has not been standardized, but <em>Exserohilum</em> spp appear to be susceptible in vitro to amphotericin B and to the extended-spectrum azoles, such as <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, but <strong>not</strong> <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (<a href=\"image.htm?imageKey=ID%2F90199\" class=\"graphic graphic_table graphicRef90199 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4-11\" class=\"abstract_t\">4-11</a>]. In the absence of susceptibility breakpoints or outcome data, minimum inhibitory concentration results are difficult to interpret [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/8\" class=\"abstract_t\">8</a>]. Antifungal susceptibility testing is discussed in greater detail separately. (See <a href=\"topic.htm?path=antifungal-susceptibility-testing\" class=\"medical medical_review\">&quot;Antifungal susceptibility testing&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H811229\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The United States Centers for Disease Control and Prevention (CDC) issued treatment recommendations for patients affected by the outbreak [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4,5,12\" class=\"abstract_t\">4,5,12</a>]. Our recommendations reflect those of the CDC. Treatment recommendations were based on case reports, in vitro susceptibility data, and the pharmacokinetics of the available antifungal agents.</p><p>The site of infection (central nervous system [CNS] versus peripheral joint) is an important consideration when determining the appropriate therapy.</p><p class=\"headingAnchor\" id=\"H811236\"><span class=\"h2\">Initial therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinicians were advised to consult an infectious diseases specialist to assist with the diagnosis, management, and follow-up, which may be complex and prolonged [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4,12\" class=\"abstract_t\">4,12</a>].</p><p class=\"headingAnchor\" id=\"H811243\"><span class=\"h3\">Meningitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After collecting cerebrospinal fluid (CSF) for culture and other studies, the CDC recommended that clinicians initiate empiric antifungal therapy in addition to routine empiric treatment for other potential pathogens until the etiology of the infection had been identified [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]. Patients were offered empiric antifungal therapy if they met the case definition of either probable or confirmed fungal meningitis (see <a href=\"#H672980052\" class=\"local\">'Case definitions'</a> above). <em>Exserohilum</em> spp and certain other fungi may grow slowly and, in many cases, were not been detected at all, even with molecular detection methods. (See <a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis#H19514050\" class=\"medical medical_review\">&quot;Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Evaluation and diagnosis'</a>.)</p><p>For patients who met the case definition of probable or confirmed fungal meningitis associated with a contaminated <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> epidural injection (see <a href=\"#H672980052\" class=\"local\">'Case definitions'</a> above), the CDC recommended antifungal therapy with<strong> </strong><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a><strong> with or without </strong><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a><strong> (AmBisome) </strong>[<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Specific recommendations during the outbreak included the following [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> should be given at 6 <span class=\"nowrap\">mg/kg</span> every 12 hours, which is a higher dose than is typical for other fungal infections. The same dosing is recommended regardless of whether voriconazole is being given intravenously (IV) or orally.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>High-dose <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> is recommended because ensuring rapid and adequate penetration of the CNS is essential. In addition, the high dose should allow adequate blood levels to be attained quickly. We suggest that patients continue on a high dose for the duration of treatment, if possible.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For most patients, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> should be given IV initially. Patients who are initially given IV voriconazole can be switched to oral voriconazole once they are stable and improving if they have no contraindications to oral therapy. Patients with mild disease who are able to take oral voriconazole and who can be monitored closely can be given oral voriconazole for initial therapy at the clinician's discretion. Oral voriconazole has excellent bioavailability, exceeding 90 percent [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/13\" class=\"abstract_t\">13</a>]. Thus, the target voriconazole trough concentration can be achieved using oral voriconazole, but it may require a slightly higher dose or may take longer to achieve than the IV formulation if problems with absorption occur. Oral voriconazole should be taken at least one hour before or after a meal.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients with meningitis who are severely ill (eg, severe headache <span class=\"nowrap\">and/or</span> meningismus, altered mental status, <span class=\"nowrap\">and/or</span> significant pleocytosis) should be given IV <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> initially, whereas those who have mild signs <span class=\"nowrap\">and/or</span> symptoms (eg, mild headache, normal mental status, and mild pleocytosis) can be started on oral voriconazole (at the same as weight-based dosing).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> has good CNS penetration [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/14-16\" class=\"abstract_t\">14-16</a>], with CSF concentrations ranging from 22 to 100 percent of serum concentrations (median 46 percent) in a study that assessed 36 CSF samples from 14 patients [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/15\" class=\"abstract_t\">15</a>]. Among five patients in this outbreak, CSF voriconazole concentrations were approximately 50 percent of serum concentrations [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/17\" class=\"abstract_t\">17</a>]. Among the azoles with activity against molds (voriconazole, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>), voriconazole has the best CNS penetration [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/18\" class=\"abstract_t\">18</a>]. Voriconazole concentrations in both the serum and CSF exceed the minimum inhibitory concentration for many dematiaceous fungi [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H8\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis#H7\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;, section on 'Voriconazole'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>It is anticipated that many patients could have neurologic symptoms, such as hallucinations, visual changes (changes in color vision, photopsia), and other adverse effects on the high dosage of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>. The development of hallucinations has been associated with high serum voriconazole concentrations and can be frightening to patients. Dose reduction will be required if this occurs. In contrast, the visual changes are usually benign and dose reduction is not necessary. However, these visual changes can interfere with driving a motor vehicle. Monitoring of serum trough concentrations of voriconazole is important to decrease the rate of some of these adverse effects.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Dose adjustments may be necessary in certain patients, such as children (who may require a higher dose), patients with hepatic impairment (who may require a lower dose), and those who appear to be <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> hypermetabolizers.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with meningitis who are severely ill (eg, severe headache <span class=\"nowrap\">and/or</span> meningismus, altered mental status, <span class=\"nowrap\">and/or</span> significant pleocytosis) and for patients who do not improve or who worsen clinically (including developing a new site of infection) on <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> monotherapy, we suggest combination therapy with <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (AmBisome; 5 to 6 <span class=\"nowrap\">mg/kg</span> IV every 24 hours) <strong>plus</strong> IV voriconazole (6 <span class=\"nowrap\">mg/kg</span> every 12 hours). A higher dose of liposomal amphotericin B (7.5 <span class=\"nowrap\">mg/kg</span> IV every 24 hours) can be given to patients who are not improving with the initial dosing, but clinicians should be aware of the increased risk of nephrotoxicity with the higher dose.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The liposomal preparation of amphotericin B is preferred over other lipid formulations for CNS infections because it appears to achieve higher concentrations in the brain compared with other lipid formulations or <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (based on animal data) [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Nephrotoxicity is a common complication of amphotericin B therapy, even with the lipid formulations. Administration of normal saline prior to infusion should be used to minimize the risk of nephrotoxicity; we suggest 1 liter of normal saline for patients who can tolerate it. For patients who cannot tolerate such a large fluid bolus, we suggest giving 500 mL of normal saline if possible. Hypokalemia and hypomagnesemia have been especially problematic, and supplementation of these electrolytes is essential.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who are unable to tolerate <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> monotherapy, <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (5 to 6 <span class=\"nowrap\">mg/kg</span> IV every 24 hours) can be used as an alternative to voriconazole.</p><p/><p>In patients who develop nonsevere adverse effects (eg, visual changes with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or minor elevations in creatinine with <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>), first-line therapy can be continued in many cases, with dose reduction as indicated [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]. In patients who have had a severe adverse reaction to voriconazole <span class=\"nowrap\">and/or</span> amphotericin B and who have a contraindication to the other first-line agent, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> can be used, but the decision to change the antifungal regimen should be made in consultation with an infectious diseases specialist experienced in the treatment of invasive fungal infections. It is important to note that posaconazole and itraconazole have variable pharmacokinetics in the CNS, and their effectiveness for the treatment of infections associated with the outbreak has not been established.</p><p>Patients taking <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> for infections caused by this outbreak complained of a &quot;foggy&quot; feeling, difficulty making decisions, forgetfulness, fatigue, nausea, anorexia, chapped lips, and alopecia and nail changes [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/21\" class=\"abstract_t\">21</a>] in addition to the expected rash, photosensitivity, hallucinations, visual toxicities, and liver function test abnormalities. The adverse effects associated with voriconazole are discussed in greater detail separately. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H11\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Adverse effects'</a>.)</p><p>Higher than expected rates of nephrotoxicity due to amphotericin B were reported as part of this outbreak, likely reflecting the high daily dose and the advanced age of many patients [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Monitoring during therapy is discussed below. (See <a href=\"#H811264\" class=\"local\">'Monitoring during therapy'</a> below.)</p><p>The use of intrathecal amphotericin B was <strong>not</strong> recommended due to limited data on its efficacy or associated toxicities. Adjuvant glucocorticoid therapy was also <strong>not</strong> recommended since its efficacy has not been proven and it may be harmful.</p><p class=\"headingAnchor\" id=\"H811250\"><span class=\"h3\">Injection site (parameningeal) infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During the outbreak, the CDC recommended that most patients with epidural abscess, phlegmon, discitis, vertebral osteomyelitis, <span class=\"nowrap\">and/or</span> arachnoiditis initially receive IV <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> at a dose of 6 <span class=\"nowrap\">mg/kg</span> every 12 hours, which is a higher dose than is typical for other fungal infections [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4,12\" class=\"abstract_t\">4,12</a>]. Patients could be switched to oral voriconazole once they were stable and improving if they were expected to have adequate oral absorption. Patients with mild disease who were able to take oral voriconazole and who could be monitored closely could be given oral voriconazole for initial therapy at the clinician's discretion. Other considerations regarding the use of voriconazole are discussed above. (See <a href=\"#H811243\" class=\"local\">'Meningitis'</a> above.)</p><p>For patients who developed magnetic resonance imaging (MRI) findings of an epidural abscess, epidural phlegmon, vertebral osteomyelitis <span class=\"nowrap\">and/or</span> discitis, <span class=\"nowrap\">and/or</span> arachnoiditis while receiving <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> for meningitis, the addition of <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> 5 to 6 <span class=\"nowrap\">mg/kg</span> IV once daily to the antifungal regimen was suggested [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]. For patients who had disease progression on voriconazole monotherapy <span class=\"nowrap\">and/or</span> who were clinically unstable, combination therapy with liposomal amphotericin B (AmBisome) <strong>plus</strong> voriconazole could be considered.</p><p>Patients with osteomyelitis likely required a longer duration of therapy than patients with meningitis (see <a href=\"#H811271\" class=\"local\">'Duration of therapy'</a> below). It was suggested that a neurosurgeon be consulted early for patients with epidural abscess, phlegmon, discitis, vertebral osteomyelitis, or arachnoiditis. Patients with epidural abscesses may have required operative debridement in addition to antifungal therapy. Those who had arachnoiditis were generally treated with antifungal therapy, but some required operative intervention. Monitoring during therapy is discussed below. (See <a href=\"#H811264\" class=\"local\">'Monitoring during therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H811257\"><span class=\"h3\">Osteoarticular infection not involving the spine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During the outbreak, routine antibacterial therapy for septic arthritis <span class=\"nowrap\">and/or</span> osteomyelitis was suggested according to the judgment of the treating clinician while awaiting results of diagnostic tests [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4\" class=\"abstract_t\">4</a>]. In patients with septic arthritis who were clinically stable, it was considered reasonable to wait for 48 to 72 hours before starting empiric antifungal therapy to allow time for the identification of alternative processes (eg, bacterial arthritis, crystal-induced arthritis).</p><p>When antifungal therapy was initiated for patients who met the case definition of probable or confirmed fungal osteoarticular infection not involving the spine associated with a contaminated <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> epidural injection (see <a href=\"#H672980052\" class=\"local\">'Case definitions'</a> above), the CDC recommended antifungal therapy with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a><strong> with or without a lipid formulation of amphotericin B </strong>as follows [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Specific recommendations during the outbreak included the following [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4\" class=\"abstract_t\">4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> should be given beginning with a loading dose of 6 <span class=\"nowrap\">mg/kg</span> every 12 hours for two doses, followed by 4 <span class=\"nowrap\">mg/kg</span> every 12 hours thereafter.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients who have severe osteoarticular infection should be started on IV <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, but those with mild infection may be started on oral voriconazole. Voriconazole has excellent penetration into the joint space [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Patients who are initially given IV <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> can be switched to oral voriconazole once they are stable and improving if they are expected to have adequate oral absorption. Dose adjustments may be necessary in certain patients, such as children (who may require a higher dose), patients with hepatic impairment (who may require a lower dose), and those who appear to be voriconazole hypermetabolizers.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with osteoarticular infection who have disease progression on <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> monotherapy <span class=\"nowrap\">and/or</span> who are clinically unstable, combination therapy with a lipid formulation of amphotericin B (eg, <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> [AmBisome], <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">amphotericin B lipid complex</a> [ABLC, Abelcet]) <strong>plus</strong> voriconazole should be considered. When a lipid formulation of amphotericin B is used, it should be given at a dose of 5 <span class=\"nowrap\">mg/kg</span> IV every 24 hours. (See <a href=\"topic.htm?path=pharmacology-of-amphotericin-b#H16\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;, section on 'Lipid-based amphotericin B formulations'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Nephrotoxicity is a common complication of amphotericin B therapy, even with the lipid formulations. Administration of normal saline prior to infusion should be used to minimize the risk of nephrotoxicity; we suggest 1 liter of normal saline for patients who can tolerate it. For patients who cannot tolerate such a large fluid bolus, we suggest giving 500 mL of normal saline if possible. Hypokalemia and hypomagnesemia have been especially problematic, and supplementation of these electrolytes is essential.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alternative therapies for patients who have osteoarticular infection and who are unable to tolerate treatment with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> include lipid formulations of amphotericin B, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>. <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> should <strong>not</strong> be used since it lacks activity against <em>Exserohilum</em>. Serum concentrations of posaconazole and itraconazole must be monitored when these agents are used. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H30\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Posaconazole'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H27\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Itraconazole'</a>.)</p><p/><p>Monitoring during therapy is discussed below. (See <a href=\"#H811264\" class=\"local\">'Monitoring during therapy'</a> below.)</p><p>In addition to antifungal therapy, in patients with severe septic arthritis (based on clinical findings or diagnostic testing), consideration of arthroscopy with joint lavage <span class=\"nowrap\">and/or</span> debridement by an orthopedic surgeon was recommended. (See <a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis#H101033353\" class=\"medical medical_review\">&quot;Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis&quot;, section on 'Osteoarticular infection'</a>.)</p><p class=\"headingAnchor\" id=\"H811264\"><span class=\"h2\">Monitoring during therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients receiving antifungal therapy required close monitoring during therapy for adverse effects and drug-drug interactions [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12,19,22\" class=\"abstract_t\">12,19,22</a>]. Although the appropriate frequency of laboratory and symptom monitoring varies from patient to patient depending on comorbidities and the development of toxicities, during the outbreak, we suggested the following frequencies of testing as general guidelines for patients receiving <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or a lipid formulation of amphotericin B:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients receiving <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, we suggest at least weekly monitoring of liver function tests because voriconazole can be hepatotoxic. Patients should also be counseled about the risk of hepatotoxicity and the signs and symptoms of hepatitis (eg, nausea, right upper quadrant pain, jaundice). (See <a href=\"topic.htm?path=pharmacology-of-azoles#H12\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Hepatotoxicity'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest checking a trough concentration of <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> on the fifth day of therapy; the dose should be adjusted to attain a trough concentration of &gt;2 <span class=\"nowrap\">mcg/mL</span> and &lt;5 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]. Trough concentrations below 2 <span class=\"nowrap\">mcg/mL</span> warrant an increase in the voriconazole dose. On the other hand, serum drug concentrations above 5 <span class=\"nowrap\">mcg/mL</span> warrant a reduction in the voriconazole dose, because they have been associated with an increased risk of hepatotoxicity and neurotoxicity [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/22-24\" class=\"abstract_t\">22-24</a>]. Once the target trough concentration has been reached, trough concentrations should be checked weekly for the initial four to six weeks of therapy and the dose should be adjusted to maintain a trough concentration within the goal range. These recommendations apply to patients receiving either the IV or oral formulation of voriconazole. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H28\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinicians should monitor patients for toxicities, not just <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> levels [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]. We suggest careful questioning of the patient about neurologic symptoms. As noted above, it is anticipated that many patients could have hallucinations and visual changes (changes in color vision, photopsia), particularly on the high dosage of voriconazole. The development of hallucinations has been associated with high serum voriconazole concentrations and can be frightening to patients. If a patient has hallucinations, a serum voriconazole trough concentration should be checked promptly and the voriconazole dose should be reduced if it is &gt;5 <span class=\"nowrap\">mcg/mL</span>. In contrast, the visual changes are usually benign and dose reduction is not necessary. However, these visual changes can interfere with driving a motor vehicle.</p><p/><p class=\"bulletIndent1\">Among 297 patients receiving <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, the median daily dose was 6 <span class=\"nowrap\">mg/kg</span> every 12 hours [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/9\" class=\"abstract_t\">9</a>]. Of these individuals, 55 (19 percent) had an aspartate aminotransferase or alanine aminotransferase concentration &gt;120 <span class=\"nowrap\">U/liter,</span> 77 (26 percent) had visual disturbances, and 49 (16 percent) had hallucinations.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients at risk for QT prolongation (eg, known QT prolongation, concomitant medications that can prolong the QT interval [eg, fluoroquinolones, <a href=\"topic.htm?path=citalopram-drug-information\" class=\"drug drug_general\">citalopram</a>, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>], hypokalemia, hypomagnesemia), the QTc should be evaluated at baseline and periodically during therapy since <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> can prolong the QT interval. The risk of QT prolongation may be worsened by the addition of amphotericin B since it can cause hypokalemia and hypomagnesemia. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H23\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H34\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Selected clinical effects'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> has many important drug-drug interactions that clinicians must consider when initiating therapy or altering the dose. This is discussed in detail separately. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H31\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Drug interactions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients receiving a lipid formulation of amphotericin B, we suggest daily monitoring of renal function and electrolytes since amphotericin B formulations can cause acute kidney injury and electrolyte wasting. Potassium wasting can be severe and must be monitored closely because of the risk of QTc prolongation. Clinicians should also be aware that lipid formulations of amphotericin B can cause infusion-related reactions, including chest pain, dyspnea, hypoxia, abdominal pain, flushing, and urticaria. Among 178 patients treated with amphotericin B (nearly all of whom received a liposomal formulation), acute kidney injury (serum creatinine &gt;2 times baseline) developed in 46 patients (26 percent), with 3 patients requiring dialysis [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/9\" class=\"abstract_t\">9</a>]. The median time to acute kidney injury was five days (interquartile range four to eight days). (See <a href=\"topic.htm?path=amphotericin-b-nephrotoxicity\" class=\"medical medical_review\">&quot;Amphotericin B nephrotoxicity&quot;</a> and <a href=\"topic.htm?path=pharmacology-of-amphotericin-b#H16\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;, section on 'Lipid-based amphotericin B formulations'</a>.)</p><p/><p>There has been concern about the potential for nephrotoxicity of IV <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> in patients with renal dysfunction because the IV formulation contains sulphobutylether-beta-cyclodextrin (SBECD); SBECD is a solubilizing agent that is renally cleared and that has been associated with nephrotoxicity in rats as a result of renal tubule vacuolation [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/25,26\" class=\"abstract_t\">25,26</a>]. The manufacturer has recommended that IV voriconazole generally be avoided in patients with renal insufficiency (creatinine clearance &lt;50 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/13\" class=\"abstract_t\">13</a>]. However, in a retrospective study that evaluated renal function in 166 patients receiving IV or oral voriconazole (one-quarter of whom had a glomerular filtration rate &lt;50 <span class=\"nowrap\">mL/min</span> at baseline and received IV voriconazole), neither baseline renal function nor route of administration was associated with worsening renal function [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/27\" class=\"abstract_t\">27</a>]. During the outbreak, IV voriconazole was recommended for patients who require it even if renal insufficiency is present [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H16\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Voriconazole'</a>.)</p><p class=\"headingAnchor\" id=\"H811271\"><span class=\"h2\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The appropriate duration of therapy has not been established and varied depending on individual patient circumstances and the severity and location of disease [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4,12\" class=\"abstract_t\">4,12</a>]. During the outbreak, the following recommendations were made about the duration of therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with meningitis alone, therapy will likely be required for a <strong>minimum</strong> of three months. Before stopping therapy, the patient must have a lumbar puncture showing that pleocytosis has resolved.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with injection site (parameningeal) infection, therapy will likely be required for a <strong>minimum</strong> of three to six months.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with severe CNS and parameningeal disease, including stroke, arachnoiditis, osteomyelitis, and discitis and for those who have underlying immunosuppression or persistent CSF abnormalities, therapy will likely need to be continued for six months to one year.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with osteoarticular infections not involving the spine, the duration of therapy is not known, but a minimum of three and possibly six months may be needed.</p><p/><p>The decision to tailor or discontinue therapy will depend in part on the patient's response to therapy. Decisions about the duration of therapy should be made in consultation with an infectious diseases specialist who is experienced with the management of invasive fungal infections. After completion of therapy, clinicians should be vigilant for potential relapse of infection.</p><p>Because the appropriate duration of therapy and the potential for relapse are unknown, it is essential to closely monitor patients in whom antifungal therapy has been discontinued [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/12\" class=\"abstract_t\">12</a>]. Patients with recurrent symptoms or worsening pain should be evaluated immediately. Clinicians should have a low threshold for performing a lumbar puncture <span class=\"nowrap\">and/or</span> MRI to detect relapsed infection.</p><p class=\"headingAnchor\" id=\"H811278\"><span class=\"h2\">Evidence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the rarity of infections caused by <em>Exserohilum</em> spp and other dematiaceous fungi, there are no randomized trials that have evaluated the optimal therapy of invasive infections, and clinical experience is limited. In addition, susceptibility testing of the dematiaceous fungi has not been standardized, but <em>Exserohilum</em> spp appear to be susceptible in vitro to amphotericin B and to the extended-spectrum azoles, such as <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, and <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> but <strong>not</strong> <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (<a href=\"image.htm?imageKey=ID%2F90199\" class=\"graphic graphic_table graphicRef90199 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/4-8\" class=\"abstract_t\">4-8</a>] (see <a href=\"#H920083787\" class=\"local\">'Antifungal susceptibility'</a> above). Voriconazole has excellent bioavailability and good CNS penetration (see <a href=\"#H811243\" class=\"local\">'Meningitis'</a> above). Neither posaconazole nor itraconazole achieve substantial levels in the CSF, and their oral absorption is unpredictable [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Case reports from prior to the outbreak have described successful treatment in some patients with <em>Exserohilum</em> spp infections with either <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> or amphotericin B [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/28-33\" class=\"abstract_t\">28-33</a>]. Other patients have died despite therapy; immunosuppression is likely to have contributed to mortality in cases not associated with the 2012 outbreak [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/31\" class=\"abstract_t\">31</a>].</p><p class=\"headingAnchor\" id=\"H811299\"><span class=\"h1\">OUTCOMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The outcomes of patients affected by the outbreak were significantly worse at the beginning of the outbreak compared with later in the outbreak. Of 82 patients diagnosed with meningitis before all steps were taken to contain the outbreak, 23 (28 percent) died within 60 days of diagnosis [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/34\" class=\"abstract_t\">34</a>]. In contrast, after October 4, 2016, the date that the outbreak was first publicized widely, 17 of 307 patients with meningitis (6 percent) died.</p><p>In a separate study that included 328 patients, there were 26 deaths (7.9 percent) [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/9\" class=\"abstract_t\">9</a>]. Among the patients who died, 22 (85 percent) had stroke, 2 (8 percent) had meningitis with epidural abscess, 1 (4 percent) had meningitis only, and 1 (4 percent) had arachnoiditis without stroke. The majority of deaths (58 percent) occurred before October 15, 2012. The median survival time among those who died was 9 days (interquartile range 7 to 19 days) after hospital admission. Among patients with meningitis, independent risk factors for death or stroke included older age, presence of fever, altered mental status, and a high cerebrospinal fluid (CSF) white blood cell (WBC) count. The CSF WBC count upon presentation was positively associated with the case-fatality rate (CSF WBC &le;100 <span class=\"nowrap\">cells/microL:</span> 0 percent; CSF WBC 100 to 249 <span class=\"nowrap\">cells/microL:</span> 11 percent; CSF WBC 250 to 499 <span class=\"nowrap\">cells/microL:</span> 13 percent; CSF WBC &gt;500 <span class=\"nowrap\">cells/microL:</span> 14 percent).</p><p>Preliminary data from a long-term follow-up study published in 2015 provided the following information [<a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/35\" class=\"abstract_t\">35</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients received antifungal therapy for at least 6 months after diagnosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>By 12 months after the initial diagnosis, 192 of 455 patients (42 percent) followed in the study were considered cured (defined as no radiologic or laboratory evidence of fungal infection, resolved or improved signs and symptoms, and not having received antifungal therapy for at least 3 months), 185 (41 percent) were no longer receiving antifungal therapy but did not meet the definition of cure, 32 (7 percent) were still receiving antifungal therapy, 35 (8 percent) had died (with 24 fatalities attributed to outbreak-associated infections), and 11 (2 percent) had incomplete follow-up data.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eight cases of relapsed fungal infection after antifungal therapy was stopped have been reported (1 percent of 753 cases). Median time to relapse was 90 days (range 20 to 662 days). One case of relapsed disease occurred 21 months after cessation of therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Follow-up data for as long as two years currently are being analyzed.</p><p/><p class=\"headingAnchor\" id=\"H811313\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A multistate outbreak of fungal central nervous system (CNS) infection and septic arthritis was detected in the United States in late September 2012. Over 700 patients who received epidural injections of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> produced at a single compounding center (New England Compounding Center) developed meningitis with or without posterior circulation stroke <span class=\"nowrap\">and/or</span> spinal or paraspinal infections, and more than 30 patients who received intra-articular injections of the same drug developed osteoarticular infections. (See <a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The United States Centers for Disease Control and Prevention (CDC) issued treatment recommendations for patients affected by the outbreak. Specific recommendations that were made during the outbreak are summarized below. (See <a href=\"#H811229\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>It was recommended that all patients who met the case definition of probable or confirmed fungal meningitis associated with a contaminated <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> epidural injection be given antifungal therapy <strong>immediately</strong>. The CDC also recommended that such patients receive <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> with or without <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>. (See <a href=\"#H811243\" class=\"local\">'Meningitis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>When antifungal therapy was initiated for patients who met the case definition of probable or confirmed fungal osteoarticular infection associated with a contaminated <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> injection (see <a href=\"#H672980052\" class=\"local\">'Case definitions'</a> above), patients were advised to take <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> with or without a lipid formulation of amphotericin B. (See <a href=\"#H811250\" class=\"local\">'Injection site (parameningeal) infections'</a> above and <a href=\"#H811257\" class=\"local\">'Osteoarticular infection not involving the spine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The appropriate duration of therapy varied depending on individual patient circumstances and the severity and location of disease. Patients generally required long courses of antifungal therapy. (See <a href=\"#H811271\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The outcomes of patients affected by the outbreak were significantly worse at the beginning of the outbreak compared with later in the outbreak. The 60-day mortality rate of patients with meningitis was 28 percent before the outbreak was publicized widely versus 6 percent after it was publicized. (See <a href=\"#H811299\" class=\"local\">'Outcomes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As of October 2015, eight cases of relapse of fungal infection after antifungal therapy had been reported (1 percent of 753 cases). Median time to relapse was 90 days (range 20 to 662 days). One case of relapsed disease occurred 21 months after cessation of therapy. (See <a href=\"#H811299\" class=\"local\">'Outcomes'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/1\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:839.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Multistate fungal meningitis outbreak - current case count. http://www.cdc.gov/hai/outbreaks/meningitis-map-large.html (Accessed on November 11, 2015).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Case definitions for meningitis and septic arthritis. http://www.cdc.gov/hai/outbreaks/clinicians/casedef_multistate_outbreak.html (Accessed on October 31, 2012).</li><li class=\"breakAll\">Centers for Disease Control and Prevention. Interim treatment guidance for osteoarticular infections associated with injection of contaminated steroid products. http://www.cdc.gov/hai/outbreaks/clinicians/interim_treatment_options_septic_arthritis.html (Accessed on October 24, 2012).</li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/5\" class=\"nounderline abstract_t\">Pappas PG, Kontoyiannis DP, Perfect JR, Chiller TM. Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States. Antimicrob Agents Chemother 2013; 57:1573.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/6\" class=\"nounderline abstract_t\">da Cunha KC, Sutton DA, Gen&eacute; J, et al. Molecular identification and in vitro response to antifungal drugs of clinical isolates of Exserohilum. Antimicrob Agents Chemother 2012; 56:4951.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/7\" class=\"nounderline abstract_t\">Stevens DA. Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother 2013; 57:1567.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/8\" class=\"nounderline abstract_t\">Lockhart SR, Pham CD, Gade L, et al. Preliminary laboratory report of fungal infections associated with contaminated methylprednisolone injections. J Clin Microbiol 2013; 51:2654.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/9\" class=\"nounderline abstract_t\">Chiller TM, Roy M, Nguyen D, et al. Clinical findings for fungal infections caused by methylprednisolone injections. N Engl J Med 2013; 369:1610.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/10\" class=\"nounderline abstract_t\">Revankar SG, Moudgal V, Chandrasekar P, Sobel JD. In vitro studies of Exserohilum rostratum with antifungal drugs and methylprednisolone. Antimicrob Agents Chemother 2014; 58:3564.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/11\" class=\"nounderline abstract_t\">Chowdhary A, Hagen F, Curfs-Breuker I, et al. In Vitro Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates. Antimicrob Agents Chemother 2015; 59:6642.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Interim treatment guidance for central nervous system and parameningeal infections associated with injection of contaminated steroid products. http://www.cdc.gov/hai/outbreaks/clinicians/guidance_cns.html (Accessed on March 06, 2013).</li><li class=\"breakAll\">VFEND IV (voriconazole) for injection, VFEND tablets (voriconazole), VFEND (voriconazole) oral suspension prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021266s023,021267s024,021630s013lbl.pdf (Accessed on October 17, 2012).</li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/14\" class=\"nounderline abstract_t\">Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55:925.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/15\" class=\"nounderline abstract_t\">Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37:728.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/16\" class=\"nounderline abstract_t\">Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97:663.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/17\" class=\"nounderline abstract_t\">Kerkering TM, Grifasi ML, Baffoe-Bonnie AW, et al. Early clinical observations in prospectively followed patients with fungal meningitis related to contaminated epidural steroid injections. Ann Intern Med 2013; 158:154.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/18\" class=\"nounderline abstract_t\">Nau R, S&ouml;rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23:858.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/19\" class=\"nounderline abstract_t\">Kauffman CA, Pappas PG, Patterson TF. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013; 368:2495.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/20\" class=\"nounderline abstract_t\">Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000; 182:274.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/21\" class=\"nounderline abstract_t\">Malani AN, Kerr L, Obear J, et al. Alopecia and nail changes associated with voriconazole therapy. Clin Infect Dis 2014; 59:e61.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/22\" class=\"nounderline abstract_t\">Shoham S, Marr KA. Treatment of iatrogenic fungal infections: a black mold defines a new gray zone in medicine. Ann Intern Med 2013; 158:208.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/23\" class=\"nounderline abstract_t\">Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/24\" class=\"nounderline abstract_t\">Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42:1859.</a></li><li class=\"breakAll\">FDA Antiviral Drugs Advisory Committee. Briefing document for voriconazole\r\n(oral and intravenous formulations). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_pfizer.pdf (Accessed on May 09, 2012).</li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/26\" class=\"nounderline abstract_t\">Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010; 99:3291.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/27\" class=\"nounderline abstract_t\">Neofytos D, Lombardi LR, Shields RK, et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis 2012; 54:913.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/28\" class=\"nounderline abstract_t\">Derber C, Elam K, Bearman G. Invasive sinonasal disease due to dematiaceous fungi in immunocompromised individuals: case report and review of the literature. Int J Infect Dis 2010; 14 Suppl 3:e329.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/29\" class=\"nounderline abstract_t\">Adler A, Yaniv I, Samra Z, et al. Exserohilum: an emerging human pathogen. Eur J Clin Microbiol Infect Dis 2006; 25:247.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/30\" class=\"nounderline abstract_t\">Lin SC, Sun PL, Ju YM, Chan YJ. Cutaneous phaeohyphomycosis caused by Exserohilum rostratum in a patient with cutaneous T-cell lymphoma. Int J Dermatol 2009; 48:295.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/31\" class=\"nounderline abstract_t\">Aquino VM, Norvell JM, Krisher K, Mustafa MM. Fatal disseminated infection due to Exserohilum rostratum in a patient with aplastic anemia: case report and review. Clin Infect Dis 1995; 20:176.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/32\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy--United States, July-November 2002. MMWR Morb Mortal Wkly Rep 2002; 51:1109.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/33\" class=\"nounderline abstract_t\">Perfect JR. Iatrogenic fungal meningitis: tragedy repeated. Ann Intern Med 2012; 157:825.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/34\" class=\"nounderline abstract_t\">Smith RM, Derado G, Wise M, et al. Estimated deaths and illnesses averted during fungal meningitis outbreak associated with contaminated steroid injections, United States, 2012-2013. Emerg Infect Dis 2015; 21:933.</a></li><li><a href=\"https://www.uptodate.com/contents/outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-treatment/abstract/35\" class=\"nounderline abstract_t\">McCotter OZ, Smith RM, Westercamp M, et al. Update on Multistate Outbreak of Fungal Infections Associated with Contaminated Methylprednisolone Injections, 2012-2014. MMWR Morb Mortal Wkly Rep 2015; 64:1200.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 87286 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H811313\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H811222\" id=\"outline-link-H811222\">INTRODUCTION</a></li><li><a href=\"#H672980052\" id=\"outline-link-H672980052\">CASE DEFINITIONS</a></li><li><a href=\"#H920083787\" id=\"outline-link-H920083787\">ANTIFUNGAL SUSCEPTIBILITY</a></li><li><a href=\"#H811229\" id=\"outline-link-H811229\">TREATMENT</a><ul><li><a href=\"#H811236\" id=\"outline-link-H811236\">Initial therapy</a><ul><li><a href=\"#H811243\" id=\"outline-link-H811243\">- Meningitis</a></li><li><a href=\"#H811250\" id=\"outline-link-H811250\">- Injection site (parameningeal) infections</a></li><li><a href=\"#H811257\" id=\"outline-link-H811257\">- Osteoarticular infection not involving the spine</a></li></ul></li><li><a href=\"#H811264\" id=\"outline-link-H811264\">Monitoring during therapy</a></li><li><a href=\"#H811271\" id=\"outline-link-H811271\">Duration of therapy</a></li><li><a href=\"#H811278\" id=\"outline-link-H811278\">Evidence</a></li></ul></li><li><a href=\"#H811299\" id=\"outline-link-H811299\">OUTCOMES</a></li><li><a href=\"#H811313\" id=\"outline-link-H811313\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/87286|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/86772\" class=\"graphic graphic_picture\">- Exserohilum rostratum</a></li></ul></li><li><div id=\"ID/87286|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/90199\" class=\"graphic graphic_table\">- Exserohilum susceptibility</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=amphotericin-b-nephrotoxicity\" class=\"medical medical_review\">Amphotericin B nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antifungal-susceptibility-testing\" class=\"medical medical_review\">Antifungal susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis\" class=\"medical medical_review\">Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">Pharmacology of amphotericin B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=septic-arthritis-in-adults\" class=\"medical medical_review\">Septic arthritis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">Treatment and prevention of invasive aspergillosis</a></li></ul></div></div>","javascript":null}